Read Dr. Rubin's Comments on New Study Comparing HRQoL of Laparoscopic Ileocaecal Resection and Infliximab Treatment

Surgery an Alternative to Infliximab for Some People With Crohn’s Disease
By Marilynn Larkin

Dr. David Rubin, Chief of the Section of Gastroenterology, Hepatology, and Nutrition at the University of Chicago Medicine, agreed: “For some patients, as difficult as it may seem, a surgical intervention early in their disease will enable better control and, as this study shows, an excellent quality of life later.”

“I often explain to patients that one of the most significant advances in the management of CD has been our ability to prevent it after an expert surgical resection,” he said. “There is more work to be done to better understand which patients would benefit most from this approach. Nonetheless, this study provides us with the information necessary to have informed discussions with our patients about treatment options.”

Read Full Study by Dr. Willem Bemelman here